About SURMOUNT-5 SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
Understanding your predisposition can help your provider anticipate this outcome and adjust your titration schedule accordingly
Finally, maintain proper hydration (minimum 64 oz water daily) and sleep (7-9 hours nightly) to minimize metabolic stress
Potential Benefits of TB500 BPC-157 Blend: Netherlands Researchers believe that combining BPC-157 and TB-500, which each stimulate wound healing through a different biochemical mechanism, can improve recovery times and repair processes
Session 1 Session 6, dosage set by your attending physician at consult